– BELGIUM, Mont-Saint-Guibert – Celyad Oncology SA (EBR: CYAD | NASDAQ: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the appointment of Dr. Marina Udier, Ph.D. to its Board of Directors.
“I am very pleased to welcome Marina to our Board of Directors,” said CEO, Filippo Petti.
“As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from Marina’s wealth of experience as we continue to advance key elements of our pipeline with the goal of developing innovative cell therapies against cancer.”
About Dr. Marina Udier
Dr. Udier currently serves as CEO of Nouscom, a private oncology company developing next-generation immunotherapies, after joining as Chief Operating Officer in 2016 from Versant Ventures, where she was Operating Principal. Prior to Versant, she held various senior development and commercial roles at Novartis Pharma in Basel. As the Global Commercial Head, she developed the global strategy for a point of care diagnostics platform. Her experience in molecular diagnostics includes In Vitro Diagnostics development; she led development of a Companion Diagnostics for RYDAPTTM, the first approved AML drug in over three decades. Marina managed the Global Neurodegeneration portfolio for Novartis driving her brands to a blockbuster status. She spent five years with McKinsey & Company in Chicago, working with Healthcare Fortune 500 companies in areas of marketing, strategy and pricing.
Dr. Marina Udier said, “Celyad Oncology is at a pivotal moment in its company history with multiple candidates in the clinic and a promising array of significant milestones expected in 2021. I am honored to be part of the Celyad Oncology Board and look forward to working with the talented team to execute on the company’s strategic vision of establishing itself as an industry leader in the CAR T space.”
Dr. Udier received her Ph.D. in Organic Chemistry from Yale University. She authored peer-reviewed publications covering HIV/AIDS research.
See more about Celyad Oncology
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
